Media Release: Allianz Beach Arena for the LA28 Olympic and Paralympic Games Joins the Allianz Family of Stadiums

 First Olympic and Paralympic venue in history to display the Allianz name and the eighth member of the Allianz Family of Stadiums.

The nearly 15,000 seat temporary arena on the Long Beach waterfront will host Olympic Beach Volleyball and Paralympic Blind Football (Soccer).

Allianz unveils its customized LA28 Games emblem, marking the start of its preparations for the LA28 Olympic and Paralympic Games.

 

(BUSINESS WIRE)--For the first time in Olympic and Paralympic history, a competition venue will carry the Allianz name. The Allianz Beach Arena in Long Beach, California, for the LA28 Olympic and Paralympic Games will become the newest member of the Allianz Family of Stadiums.

From Horse Guards Parade in London to Copacabana Beach in Rio and the Eiffel Tower in Paris, Olympic Beach Volleyball has always found its home in iconic settings around the world. At the LA28 Games, that home will carry the Allianz name. Allianz is proud to help celebrate this exciting sport in Long Beach, a city in the southern part of Los Angeles County where beach volleyball is part of everyday life and local culture.

Set right on the Long Beach waterfront, the nearly 15,000 seat temporary arena will host the Olympic Beach Volleyball and the Paralympic Blind Football (Soccer) competitions. Across both competitions, the arena is expected to welcome nearly 735,000 spectators. LA28 anticipates selling approximately 14 million tickets for the Olympic and Paralympic Games in July and August 2028.

One of the biggest stadium networks in the world

As the first event-specific member of the Allianz Family of Stadiums, the Allianz Beach Arena, built solely for the LA28 Games, joins seven landmark sport venues around the world: the Allianz Arena in Munich, Allianz Stadium in Twickenham, Allianz Stadium in Sydney, Allianz Riviera in Nice, Allianz Stadion in Vienna, Allianz Stadium in Turin and Allianz Field in St. Paul, Minnesota. Now one of the biggest stadium networks in the world, it began with the Allianz Arena in 2005. Today, these venues collectively welcome around 10 million visitors every year.

"For the first time, two of Allianz’s major sports initiatives – the Allianz Family of Stadiums and our Worldwide Olympic and Paralympic partnership – come together in one venue that proudly bears the Allianz name. Beach Volleyball broke attendance records at Olympic Games Paris 2024, and having the Allianz name on its arena at the LA28 Games is a unique way to bring our brand closer to fans and strengthen our visibility as a Worldwide Olympic and Paralympic Partner," said Eike Bürgel, Global Head of Olympic and Paralympic Program at Allianz.

The Allianz Riviera in Nice hosted six football matches under a neutral name during Paris 2024. At the LA28 Games, the Allianz Beach Arena becomes the first Olympic venue to display the Allianz name. LA28 is making history as the first Olympic and Paralympic Games to offer naming rights at competition venues, creating new commercial opportunities that directly support the staging of the Games.

Allianz is also launching its LA28 Games "custom A" emblem. The "A" in the LA28 emblem is designed to change, allowing each partner to create its own interpretation. For Allianz, the design takes inspiration from the company’s Family of Stadiums, featuring the Allianz Arena in Munich and Allianz Field in St. Paul, Minnesota.

These announcements mark another step in Allianz’s preparations for the LA28 Games. Building on 20 years of partnership with the Paralympic Movement, Allianz has been a Worldwide Olympic and Paralympic Partner since 2021 and will continue to support the Games through 2032. Allianz firmly believes in the power of sport to bring people together, and no place does this better than a stadium. The Allianz Family of Stadiums and the Olympic and Paralympic Movement share this spirit, creating spaces of connection and common understanding that foster inclusive prosperity. Next up: on sand.

By the numbers

First competition date at Allianz Beach Arena: July 15, 2028.

Venue capacity: nearly 15,000 per session; nearly 735,000 total attendance.

Number of ticketed matches:

Olympics: 39 (two medal events).

Paralympics: 10 (one medal event).

Members of the Allianz Family of Stadiums: eight across seven countries.

About Allianz

The Allianz Group is one of the world’s leading insurers and asset managers, active in almost 70 countries and serving around 97 million private and corporate customers*. Our customers benefit from a broad range of personal and corporate insurance services, including property, life and health insurance, as well as assistance services, credit and global business insurance. Recognized for the seventh consecutive year as the number one global insurance brand in Interbrand’s Best Global Brands 2025 ranking, Allianz’s success is built on technology-enabled customer centricity – providing peace of mind, protection, and prevention for our customers and strengthening the resilience of individuals, communities, and societies. We are one of the world’s largest investors, managing around 791 billion euros** on behalf of our insurance customers. Furthermore, our asset managers PIMCO and Allianz Global Investors manage about 2.2 trillion euros** of third-party assets. Thanks to our systematic integration of environmental and social criteria in our business processes and investment decisions, Allianz received an MSCI ESG Rating of AAA (as of March 2026). In 2025, our 156,000 dedicated employees achieved a total business volume of 186.9 billion euros and an operating profit of 17.4 billion euros for our shareholders.

* As of December 31, 2025. Customer count reflects Allianz customers in consolidated entities that are part of the customer reporting scope only.

** As of June 30, 2026.

Mandatory corporate information: Corporate disclosures

These assessments are, as always, subject to the disclaimer provided below.

Cautionary note regarding forward-looking statements

This document includes forward-looking statements, such as prospects or expectations, that are based on management's current views and assumptions and subject to known and unknown risks and uncertainties. Actual results, performance figures, or events may differ significantly from those expressed or implied in such forward-looking statements.

Deviations may arise due to changes in factors including, but not limited to, the following: (i) the general economic and competitive situation in Allianz’s core business and core markets, (ii) the performance of financial markets (in particular market volatility, liquidity, and credit events), (iii) adverse publicity, regulatory actions or litigation with respect to the Allianz Group, other well-known companies and the financial services industry generally, (iv) the frequency and severity of insured loss events, including those resulting from natural catastrophes, and the development of loss expenses, (v) mortality and morbidity levels and trends, (vi) persistency levels, (vii) the extent of credit defaults, (viii) interest rate levels, (ix) currency exchange rates, most notably the EUR/USD exchange rate, (x) changes in laws and regulations, including tax regulations, (xi) the impact of acquisitions including related integration issues and reorganization measures, and (xii) the general competitive conditions that, in each individual case, apply at a local, regional, national, and/or global level. Many of these changes can be exacerbated by terrorist activities.

No duty to update

Allianz assumes no obligation to update any information or forward-looking statement contained herein, save for any information we are required to disclose by law.

Privacy Note Allianz SE is committed to protecting your personal data. Find out more in our privacy statement.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261026919959/en/

Permalink

https://www.aetoswire.com/en/news/2610202658467

Contacts

For further information, please contact:

Florian Amberg

Tel. +49 89 3800 15924

E-Mail: florian.amberg@allianz.com

Heidi Polke

Tel. +49 89 3800 90777

E-Mail: heidi.polke@allianz.com

Patricia Segovia

Tel. +49 89 3800 67589

E-Mail: patricia.segovia@allianz.com

 

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function

DARMSTADT, Germany - Monday, 26. October 2026



    Improvements in symptoms of pain, stiffness, and range of motion were sustained through two years

    Tumor responses remained robust1 and durable2

Not intended for U.K.-, U.S.- or Canada-based media

 

(BUSINESS WIRE) -- Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P).

"For people living with TGCT, the impact of the disease is often felt through persistent limitations in mobility, physical function and the ability to carry out everyday activities," said Vinod Ravi, MD, MS, MBA, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, an investigator on the MANEUVER trial. "What is encouraging about these two-year findings is the consistency of improvements, not only in the durability of tumor response, but across the symptoms and functional outcomes that matter to patients. Together with the observed safety profile, these results provide important insight into the potential for pimicotinib to deliver meaningful benefit over time."

The new analysis in patients initially randomized to pimicotinib found that at Week 97, mean changes from baseline were 19.6% in range of motion, -3.9 in stiffness (as measured by the Worst Stiffness Numeric Scale Rating), -3.1 in pain (as measured by the Brief Pain Inventory worst pain rating) and +7.4 in physical function (as measured by the patient-reported PROMIS-PF scale).

Tumor responses also remained robust1 and durable2 through two years. Objective Response Rate (ORR) by blinded independent review committee (BICR) per RECIST v1.1 was 76.2% (95% CI: 63.8, 86.0), remaining unchanged from the one-year analysis, while ORR per BIRC based on tumor volume score (TVS) increased from 74.6% at one year to 77.8% (95% CI: 65.5, 87.3) at two years. Median duration of response was not reached at the time of analysis, and median treatment duration was 22.6 months (range: 1.8-33.6 months) at the March 1, 2026 data cutoff. Fifty-four percent of patients initially randomized to pimicotinib remained on treatment at two years.

In MANEUVER, pimicotinib was well-tolerated, with no evidence of cholestatic hepatotoxicity or hair/skin hypopigmentation. During the randomized, double-blind treatment phase of the trial, treatment-emergent adverse events (TEAEs) leading to treatment discontinuation occurred in one patient (1.6%) treated with pimicotinib; TEAEs leading to dose reduction occurred in 7.9% (n=5) of pimicotinib-treated patients.

"These two-year findings add to the growing body of evidence from the MANEUVER study demonstrating the potential for pimicotinib to meaningfully address some of the burden of TGCT," said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The sustained improvements observed across symptoms, physical function and tumor control reinforce the potential of pimicotinib to address aspects of TGCT that can affect patients every day. These results add to our evolving understanding of the long-term benefit that pimicotinib may provide for people living with this debilitating rare tumor."

TGCT is a rare, locally aggressive tumor occurring in or around the joints leading to progressive worsening of symptoms including pain and reduced mobility of the affected joint, significantly impacting physical function in what is typically an otherwise healthy and young adult population. Patient-reported experiences indicate that up to half of people with TGCT may initially receive an incorrect diagnosis, which can delay appropriate disease management.3 If left untreated or in recurrent cases, TGCT may result in cumulative morbidity and irreversible damage to the bone, joint and surrounding tissues.

Pimicotinib was approved in China by the China National Medical Products Administration (NMPA) in December 2025 and in Canada by Health Canada in June 2026 for the treatment of adult patients with symptomatic TGCT. A regulatory application is currently under review by the U.S. Food and Drug Administration (FDA) and other regulatory agencies.

1 54% ORR as assessed by BIRC based on RECIST v1.1 at week 25 vs. 3% with placebo; p<0.0001.

2 The majority (77%) of patients with response at 25 weeks maintained this clinical benefit after an additional 12 months of treatment.

3 Stern S, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. Future Oncol. 2025;21(12):1501-1510.

About MANEUVER

The pivotal, global Phase 3 MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pimicotinib in patients with TGCT who were eligible for systemic therapy and have not received prior anti-CSF-1/CSF-1R therapy.

The ongoing study is being conducted by Abbisko Therapeutics and enrolled patients globally in U.S., Canada and Europe (n=49) and China (n=45).

In the double-blind Part 1, 94 patients were randomized 2:1 to receive either 50 mg QD of pimicotinib (n=63) or placebo (n=31) for 24 weeks. In addition to the primary endpoint of ORR at week 25, as measured by RECIST v1.1 by BICR, secondary endpoints include tumor volume score (TVS), relative range of motion, stiffness by Numeric Rating Scale (NRS), pain by Brief Pain Inventory (BPI), and physical function measured by Patient-Reported Outcomes Measurement Information System (PROMIS-PF).

After the double-blind Part 1, all eligible patients from either arm could continue to the open-label Part 2 and receive up to 24 weeks of pimicotinib treatment. Patients who completed Part 2 could then enter the open-label extension phase (Part 3) for extended treatment and safety follow-up.

About Pimicotinib (ABSK021)

Pimicotinib, developed by Abbisko Therapeutics, is a novel, orally administered, selective and potent small-molecule inhibitor of CSF-1R. Pimicotinib has been approved for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause functional limitation or relatively severe morbidity by China National Medical Products Administration (NMPA) and Health Canada. It has been granted breakthrough therapy designation (BTD) for the treatment of inoperable TGCT by the U.S. Food and Drug Administration (FDA), and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck holds worldwide commercialization rights for pimicotinib.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck generated sales of € 21.1 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261022786567/en/

Permalink
https://www.aetoswire.com/en/news/2610202658456

Contacts

Media Relations
jennifer.hunt@emdserono.com
Phone: +1 781-496-8403

Dubai Culture Opens Registration for ISEA2026 Dubai

 Dubai Culture and Arts Authority (Dubai Culture) has opened registration for the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), taking place from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data and Identity’. The symposium will be the largest edition to date, bringing together artists, researchers, and innovators from around the world to explore the intersection of art, science, and technology and exchange perspectives on the future of contemporary creative practice.

The event supports Dubai Culture’s efforts to advance the digital arts ecosystem, deliver on its Digital Arts Roadmap objectives, and empower local talent. It also reinforces Dubai’s position as a global cultural reference, a leader in innovation, a driver of the creative economy, and rooted in Emirati heritage.

The symposium combines an in-person Artistic Programme across Dubai with an Online Academic Programme accessible from anywhere in the world. The Online Academic Programme will feature Special Track panels and workshops from 6–9 November, followed by the main academic conference sessions from 10–14 November 2026.

Registration for the artistic programme across Dubai is free, while access to the online academic programme requires a paid ticket. All participants must register and will receive a personal QR code for their exclusive use at artistic programme venues. Access details for the Online Academic Programme will be sent to the email address used to book. Students receive a 50% discount when booking with a valid university email address. To register, visit isea2026.eventshub.ai.

The programme will feature over 100 artworks and 145 academic papers, more than 50 artist talks and panel discussions, and over 10 workshops, 45+ Special Track workshops, panels and presentations, seven Eco Lab workshops and more than 20 institutional presentations within the Online Academic Programme. Exhibitions, live and audio-visual performances, installations, interactive and immersive experiences, and open sessions will take place across Dubai, inviting audiences to engage with works that explore the relationship between people, place and technology.

ISEA is one of the world’s leading platforms exploring the relationship between art, science and technology. Its 31st edition will examine four core themes: Charting Constellations, Celestial Dialogues, Eco-Tech Futures and Starlinked Worlds.

Permalink

https://www.aetoswire.com/en/news/isea2026102626e

Contacts

Antoine Boghos

antoine@ciceroandbernay.com

Dubai Chambers launches world's first Agentic AI marketplace by a chamber of commerce

 Dubai, United Arab Emirates - 

Dubai Chambers has launched Chamber AI Hub, the world's first Agentic AI marketplace developed by a chamber of commerce, enabling businesses in Dubai to access ready-to-use AI agents that independently perform a range of administrative and operational tasks.

The marketplace currently offers 22 specialised AI agents across seven business functions including Compliance, Procurement, Operations, Finance, Sales, Human Resources, and Logistics. The offering is set to expand to 100 agents.

The initiative supports Dubai's efforts to accelerate the adoption of Agentic AI across the private sector, helping businesses enhance efficiency, strengthen competitiveness, and transform their operating models.

H.E. Eng. Sultan bin Saeed Al Mansoori, Chairman of Dubai Chambers, commented: “Success in the transition to Agentic AI is measured not by technology adoption alone, but by how effectively companies use these tools to address business challenges and deliver tangible results. This is why we are connecting knowledge with practical application, building capabilities, and expanding access to specialised solutions and high-quality tools that help companies adapt to change and evolve the way they work.”

The marketplace offers practical solutions for tasks including supplier evaluation, contract reviews, invoice matching, business proposal generation, recruitment screening, and customer lead scoring.

Companies can test agents in a sandbox environment before deployment, with complimentary introductory credits and subscription packages based on usage. The platform also provides readiness assessments and dashboards to monitor usage, costs, and performance. A dedicated administration portal enables companies to oversee their teams' use of AI agents.

The launch forms part of a wider two-year programme aimed at enabling more than 295,000 private sector companies to adopt Agentic AI technologies. This includes specialised training for 14,000 companies to support the integration of Agentic AI technologies into their operational processes.

To find out more, please visit: https://aihub.dubaichambers.com

About Dubai Chambers

Dubai Chambers is a non-profit public entity that supports Dubai’s vision as a global business hub by empowering businesses, providing innovative value-added services, and unlocking access to influential networks.

Permalink

https://www.aetoswire.com/en/news/dcs26102026e

Contacts

Mohamad Mouzehem

mohamad.mouzehem@dubaichamber.com

ACMC Partners with AI Resource Intelligence Company Scepter to Evaluate Critical Minerals Projects

 (BUSINESS WIRE)--Africa Critical Minerals Corporation (ACMC) and Scepter, Inc. signed an MOU to use Scepter’s AI to evaluate African critical minerals projects for ACMC’s development platform.

ACMC is building a portfolio of critical minerals projects with local African partners. It originates opportunities, secures rights, invests, and assembles the technical, development, and capital partners to advance each project. Development partners build and operate the mines. Local content, skilled jobs, and knowledge transfer are built into every project.

ScepterAir™, Scepter’s sensor-fusion and AI anomaly detection platform, has been used in methane monitoring with ExxonMobil. The companies will integrate satellite, geological, and geospatial data to identify mineral opportunities, with field validation guiding exploration and investment.

Elias Pungong, ACMC’s Chairman, commented: “Our objective is to build a portfolio of critical minerals projects in Africa that create lasting value where we work. Partners like Scepter are key to our vision: working with cutting-edge technology companies to identify and develop the strongest opportunities in Africa.”

“We want to shorten the path from mineral identification through development and commercialization,” said Philip Father, Scepter’s Founder and CEO. “We see an extraordinary opportunity to collaborate with ACMC and its local partners to unlock the value of Africa’s mineral resources and build globally competitive critical minerals industries.”

Kweku Awotwi, mining veteran and Senior Advisor to Scepter, added, “I’m excited about the transformative potential of Scepter’s technology. AI-driven resource intelligence can fundamentally change how African nations develop their mineral resources, helping them move up the value chain.”

ACMC aims to bring American technology, capital, and expertise to African mining, including through U.S. public-private partnerships supporting technical, feasibility, and infrastructure work to attract private capital.

“U.S. national security demands earlier investment in Africa’s critical minerals,” said Carrie Clark, ACMC’s Co-founder and COO. “Scepter’s technology shows how American innovation can de-risk early-stage opportunities and open the door to American capital. We support win-win development that builds long-term prosperity in the markets we operate in.”

About Africa Critical Minerals Corporation

ACMC is a U.S.-based critical minerals development platform working with local African partners. Its founding team combines decades of African mining, energy, and project finance experience with U.S. mineral ownership and upstream development. www.africacriticalmineralscorp.com

About Scepter

Scepter, Inc. develops AI-powered resource intelligence that fuses satellite, airborne, and geological data to identify, characterize, and prioritize opportunities. www.scepterair.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261026503645/en/

Permalink

https://aetoswire.com/en/news/54627850

Contacts

 

Media contacts:

John@BeAnInsider.com

TVS Motor Company Returns to EICMA With New Models for Europe

 

SINGAPORE & MILAN - 

A year after its Milan debut, TVS Motor returns with a rapidly expanding European footprint and Italian sales up 110%

Peyman Kargar to lead TVS Motor’s next phase of global growth as the company expands European footprint

 

(BUSINESS WIRE)--TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64.

EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its dealer network, aftersales capabilities and customer support infrastructure across key markets.

In Italy, its first European market, TVS now works with around 100 dealers. Retail sales in Italy are up 110% this year to September, significantly outpacing overall market growth of around 10% and reflecting strong customer acceptance of the brand.

Expanding further within Europe, the company is establishing its own national sales companies, with operations in Italy being quickly followed by France and Germany, where TVS dealerships will open soon. Elsewhere in Europe, TVS already has 18 dealers in Spain, 2 in Portugal, 4 in Hungary and 1 in Malta. Greece and Serbia will follow by the end of 2026, and Romania by March 2027.

“Last year in Milan we said we were serious about Europe. A year later, we can demonstrate what that commitment looks like,” said Peyman Kargar, President International Business, TVS Motor Company, who has been appointed Director and Chief Executive Officer effective 27 January 2027. “We have built a strong foundation in Italy, established our own presence in key markets, and strengthened our proximity to dealers and customers. This year we return to EICMA to showcase how our product portfolio, guided by TVS Motor's enduring values of innovation, quality and customer centricity, is resonating with riders across Europe.”

TVS Motor Company serves 68 million customers in more than 90 countries. Its European operation is supported by innovation and design capability in India, Bologna and the United Kingdom.

About TVS Motor Company

TVS Motor Company (BSE:532343 and NSE: TVSMOTOR), part of TVS VENU, is a reputed two and three-wheeler manufacturer globally, championing progress through sustainable mobility with four state-of-the-art manufacturing facilities located in India and Indonesia. Rooted in our 100-year legacy of trust, value, and passion for customers, it takes pride in making internationally accepted products of the highest quality through innovative and sustainable processes. TVS Motor is the only two-wheeler company to have won the prestigious Deming Prize. Our products lead in their respective categories in the J.D. Power IQS and APEAL surveys. We have been ranked No. 1 Company in the J.D. Power Customer Service Satisfaction Survey for four consecutive years. Our group company Norton Motorcycles, based in the United Kingdom, is one of the most emotive motorcycle brands in the world. TVS Motor Company endeavours to deliver the most superior customer experience across 90 countries in which we operate.

Website:

www.tvsmotor.com

Facebook:

https://www.facebook.com/tvsmotorcompany/

Instagram:

https://www.instagram.com/tvsmotorcompany

LinkedIn:

https://in.linkedin.com/company/tvs-motor-company

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261026990290/en/

Permalink

https://aetoswire.com/en/news/54628694

Contacts

Press contact

Kanika.Mehta@tvsmotor.com

David.Rogers@tvsmotor.com

Stefania.Galli@tvsmotor.com

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

 SAN CARLOS, Calif. - Saturday, 24. October 2026 AETOSWire Print 

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer

Brain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient dataset

First clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC

(BUSINESS WIRE) -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise.

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said:

“At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongside the global Phase 3 KANDELA-302 study of our CDK4 inhibitor in breast cancer, these advances mark a clear step forward as BeOne’s solid tumor pipeline moves from promising science toward medicines with the potential to improve outcomes in difficult-to-treat cancers.”

Potential first-in-class GPC3×4-1BB bispecific continues to demonstrate compelling and durable activity in heavily pretreated HCC (Proffered Paper: 1679O; October 24, 10:15–11:45 CET)

Patients with advanced HCC who progress after immunotherapy face a high unmet need, with no established standard of care and five-year survival of only approximately 20%1,2. BGB-B2033 is an investigational bispecific antibody designed to address this gap by activating 4-1BB on T cells in the presence of GPC3-expressing tumor cells, concentrating immune activation at the tumor site, and limiting systemic toxicity, a key consideration for HCC patients who frequently suffer from underlying liver disease.

Updated Phase 1 results include the first disclosure of dose-optimization data and longer follow-up from dose escalation. Among 94 patients, 93.6% had received prior PD-(L)1 therapy and 61.7% had received both PD-(L)1 therapy and a tyrosine kinase inhibitor (TKI). Highlights include:

At the recommended Phase 3 dose of 450 mg every three weeks, the confirmed objective response rate (ORR) was 36.0%, a result that exceeds efficacy observed with TKIs, which have shown an ORR of approximately 5% in late-line HCC.3

At the selected Phase 3 dose, the estimated six-month confirmed duration-of-response rate was 74.1%, with responses observed across all clinically relevant patient subgroups.

Across dose levels, Grade 3 or higher treatment-related adverse events occurred in 5.3% of patients, and treatment-related adverse events led to discontinuation in only 2.1%.

BGB-B2033 received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in December 2025, as well as Orphan Drug Designation from the FDA in March 2026 and the European Commission in October 2026 for hepatocellular carcinoma (HCC). BeOne plans to initiate global registrational clinical trials in late-line HCC by the end of 2026, while also developing plans for registrational studies in earlier treatment settings.

Initial first-in-human data from two differentiated assets advance BeOne’s emerging NSCLC portfolio

At ESMO 2026, BeOne is presenting initial clinical data in NSCLC from two biomarker-led programs with distinct mechanisms: the oral, brain-penetrant PRMT5 inhibitor, BGB-58067, and the CEA-targeting antibody-drug conjugate (ADC), BG-C477. Based on these promising data, both programs are intended to advance toward late-stage development in 2027, continuing to build BeOne’s footprint in lung cancer alongside its established program with TEVIMBRA (tislelizumab).

Brain-penetrant PRMT5 inhibitor, BGB-58067, demonstrates systemic and intracranial activity in MTAP-deficient NSCLC (Poster: 1043P; October 23, 3:15–4:00 PM CET)

BGB-58067 is a highly potent, brain-penetrant methylthioadenosine (MTA)-cooperative PRMT5 inhibitor designed to exploit the vulnerability created by MTAP deficiency. In this, the largest publicly shared data set in MTAP-deficient solid tumors, initial Phase 1 findings from 182 patients, including 83 with NSCLC, showed:

Among 75 efficacy-evaluable patients with MTAP-deficient NSCLC, confirmed ORR was 25.3% and disease control rate (DCR) was 76.0%. In the EGFR wild-type subgroup, confirmed ORR was 38.5% and DCR was 82.1%.

Median progression-free survival was 7.7 months in the overall NSCLC cohort and 8.1 months in the EGFR wild-type subgroup.

In the NSCLC cohort, an intracranial objective response rate of 30.8% was observed in patients with untreated, asymptomatic brain metastases as well as a low rate of central nervous system (CNS) progression in 2L+ NSCLC.

At daily doses of 200–400 mg (n=87), Grade 3 or higher treatment-related adverse events occurred in 27.6%, and treatment-related adverse events led to discontinuation in 5.7%. The most common treatment-related events were nausea, anemia and fatigue.

CEA-targeting ADC BG-C477 achieves encouraging response rate in previously-treated CEAhigh NSCLC (Poster: 2567P; October 26, 12:00–12:45 PM CET)

BG-C477 is the first ADC to emerge from BeOne’s internal drug discovery organization. With a proprietary CEA (or CEACAM5) targeting antibody, a highly stable conjugator, and a cleavable linker, BG-C477 is designed to deliver a potent topoisomerase I inhibitor payload directly to CEA-expressing tumor cells.

As of April 9, 2026, preliminary Phase 1 monotherapy findings from 43 heavily pretreated patients with NSCLC, including 25 with high CEA expression, showed:

Confirmed ORR was 56.0% in patients with CEAhigh NSCLC, with a disease control rate of 88.0%; confirmed ORR in the overall NSCLC population was 34.9%.

Among patients with CEAhigh NSCLC, median duration of response had not been reached. The majority of responders, as well as two patients with unconfirmed responses, remained on treatment at data cutoff.

Grade 3 or higher treatment-emergent adverse events (TEAEs) were predominantly hematologic events (anemia 14.0%, neutropenia 14.0%, thrombocytopenia 2.3%).

Updated results, with a more recent data cut-off, will be presented in the Locally Advanced NSCLC poster session on Monday, October 26 at 12:00 CET. BG-C477 received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in October 2026.

Pivotal-study update: Phase 3 KANDELA-302 trial of CDK4 inhibitor BGB-43395 now enrolling in first-line HR+/HER2-negative breast cancer (1885TiP; October 24, 12:00–12:45 PM CEST)

Building on previously reported Phase 1 activity and tolerability findings, BeOne is advancing BGB-43395, an investigational selective CDK4 inhibitor, in the global Phase 3 KANDELA-302 study (NCT07492641). The study compares BGB-43395 plus letrozole with investigator’s choice of abemaciclib, palbociclib or ribociclib plus letrozole in first-line HR+/HER2-negative advanced or metastatic breast cancer.

Enrollment began in May 2026, with patients planned across North and South America, Europe, Asia and Australia. The primary endpoint is progression-free survival by blinded independent central review, with overall survival as the key secondary endpoint.

About BGB-B2033

BGB-B2033 is a bispecific antibody targeting GPC3 (glypican 3), a tumor-specific antigen highly expressed in HCC4, and 4-1BB, a co-stimulatory receptor associated with T-cell activation and tumor reactivity in HCC.5 The molecule has been designed with reduced antibody-dependent cellular cytotoxicity (ADCC) to prevent systemic toxicity.

About BGB-58067

BGB-58067 is an investigational, oral small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5) in an MTA-dependent manner, enabling selective targeting of MTAP-deleted cancer cells. Preclinical data demonstrate enhanced selectivity compared with MTAP wild-type cells, as well as strong potency and brain penetration.

About BG-C477

BG-C477 is an investigational ADC designed to target CEA, also known as CEACAM5, a protein highly expressed in several epithelial cancers, including certain lung and gastrointestinal cancers. The molecule is designed to work as a targeted delivery system, using an antibody that specifically recognizes CEA to deliver a potent anti-cancer payload to CEA-expressing tumor cells. BG-C477 incorporates a highly stable conjugator and cleavable linker, aiming for a strong bystander effect and manageable toxicity.

About BGB-43395

BGB-43395 is an investigational cyclin-dependent kinase (CDK) 4 inhibitor being studied in a global clinical development program that includes the KANDELA-302 (NCT07492641) Phase 3 clinical trial, in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. BGB-43395 is a highly potent and selective CDK4 inhibitor that may reduce dose-limiting hematologic toxicities associated with the current CDK4/6 standard of care and improve tolerability, thereby enabling deeper CDK4 inhibition.

About BeOne

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential of BGB-B2033, BGB-58067, BG-C477 and BGB-43395 to improve outcomes for patients; BeOne’s plans to initiate global registrational clinical trials of BGB-B2033 in late-line HCC by the end of 2026 and to develop registrational studies in earlier treatment settings; the expected advancement of BGB-58067 and BG-C477 toward late-stage development in 2027; the conduct and enrollment of the KANDELA-302 study; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

To access BeOne media resources, please visit our Newsroom site.

1 Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021 Jul;12(Suppl 2):S361-S373. doi: 10.21037/jgo.2020.02.08. PMID: 34422400; PMCID: PMC8343080.

2 National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Accessed April 2026.

3 J Clin Oncol 44, 2026 (suppl 16; abstr 4002). https://www.asco.org/abstracts-presentations/261439

4 Fanching Lin et al. Novel GPC3-targeting radiopharmaceutical therapy for hepatocellular carcinoma. J Clin Oncol 42, 525-525 (2024). DOI:10.1200/JCO.2024.42.3_suppl.525

5 Kim DY et al. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, Vol. 71, No. 3, 2020. https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30881

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261024371247/en/

Permalink

https://www.aetoswire.com/en/news/2410202658445

Contacts

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com